166 related articles for article (PubMed ID: 21159177)
1. Iloprost modulates the immune response in systemic sclerosis.
D'Amelio P; Cristofaro MA; D'Amico L; Veneziano L; Roato I; Sassi F; Bisignano G; Saracco M; Pellerito R; Patanè S; Ferracini R; Pescarmona GP; Isaia GC
BMC Immunol; 2010 Dec; 11():62. PubMed ID: 21159177
[TBL] [Abstract][Full Text] [Related]
2. Prostaglandin I(2) analogues enhance already exuberant Th17 cell responses in systemic sclerosis.
Truchetet ME; Allanore Y; Montanari E; Chizzolini C; Brembilla NC
Ann Rheum Dis; 2012 Dec; 71(12):2044-50. PubMed ID: 22814427
[TBL] [Abstract][Full Text] [Related]
3. Iloprost treatment summer-suspension: effects on skin thermal properties and cytokine profile in systemic sclerosis patients.
Auriemma M; Vianale G; Reale M; Costantini E; Di Nicola M; Romani GL; Merla A; Muraro R; Amerio P
G Ital Dermatol Venereol; 2013 Apr; 148(2):209-16. PubMed ID: 23588147
[TBL] [Abstract][Full Text] [Related]
4. Cytokine production in scleroderma patients: effects of therapy with either iloprost or nifedipine.
Della Bella S; Molteni M; Mascagni B; Zulian C; Compasso S; Scorza R
Clin Exp Rheumatol; 1997; 15(2):135-41. PubMed ID: 9196864
[TBL] [Abstract][Full Text] [Related]
5. The Prostacyclin Analogue Iloprost Modulates CXCL10 in Systemic Sclerosis.
Colasanti T; Stefanantoni K; Fantini C; Corinaldesi C; Vasile M; Marampon F; Di Luigi L; Antinozzi C; Sgrò P; Lenzi A; Riccieri V; Crescioli C
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077548
[TBL] [Abstract][Full Text] [Related]
6. Evidence for increase in finger blood flow, evaluated by laser Doppler flowmetry, following iloprost infusion in patients with systemic sclerosis: a week-long observational longitudinal study.
Rotondo C; Nivuori M; Chialà A; Praino E; Matucci Cerinic M; Cutolo M; Lapadula G; Iannone F
Scand J Rheumatol; 2018 Jul; 47(4):311-318. PubMed ID: 29409385
[TBL] [Abstract][Full Text] [Related]
7. Systemic sclerosis fibroblasts show specific alterations of interferon-γ and tumor necrosis factor-α-induced modulation of interleukin 6 and chemokine ligand 2.
Antonelli A; Fallahi P; Ferrari SM; Giuggioli D; Colaci M; Di Domenicantonio A; Ferri C
J Rheumatol; 2012 May; 39(5):979-85. PubMed ID: 22422499
[TBL] [Abstract][Full Text] [Related]
8. Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.
Cestelli V; Manfredi A; Sebastiani M; Praino E; Cannarile F; Giuggioli D; Ferri C
Mod Rheumatol; 2017 Jan; 27(1):110-114. PubMed ID: 27310203
[TBL] [Abstract][Full Text] [Related]
9. Iloprost infusion reduces serological cytokines and hormones of hypoxia and inflammation in systemic sclerosis patients.
Pellicano C; Colalillo A; De Marco O; Carnazzo V; Basile U; Gigante A; Cianci R; Rosato E
Clin Exp Med; 2024 May; 24(1):109. PubMed ID: 38777916
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling in circulating endothelial cells from systemic sclerosis patients shows an altered control of apoptosis and angiogenesis that is modified by iloprost infusion.
Tinazzi E; Dolcino M; Puccetti A; Rigo A; Beri R; Valenti MT; Corrocher R; Lunardi C
Arthritis Res Ther; 2010; 12(4):R131. PubMed ID: 20609215
[TBL] [Abstract][Full Text] [Related]
11. Iloprost effects on phagocytes in patients suffering from ischaemic diseases: in vivo evidence for down-regulation of alpha M beta 2 integrin.
Mazzone A; Mazzucchelli I; Fossati G; Gritti D; Girola S; Canale C; Cusa C; Ricevuti G
Eur J Clin Invest; 1996 Oct; 26(10):860-6. PubMed ID: 8911858
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of cyclo-oxygenase pathway metabolites on cytokine production by T lymphocytes.
Della Bella S; Molteni M; Compasso S; Zulian C; Vanoli M; Scorza R
Prostaglandins Leukot Essent Fatty Acids; 1997 Mar; 56(3):177-84. PubMed ID: 9089795
[TBL] [Abstract][Full Text] [Related]
13. Iloprost enhances portal flow velocity and volume in patients with systemic sclerosis.
Zardi EM; Picardi A; Ambrosino G; Fazio VM; Dobrina A; Frego M; Afeltra A; Lumachi F
In Vivo; 2006; 20(3):377-80. PubMed ID: 16724674
[TBL] [Abstract][Full Text] [Related]
14. Effects of iloprost on adhesion molecules and F1 + 2 in peripheral ischemia.
Mazzone A; Faggioli P; Cusa C; Stefanin C; Rondena M; Morelli B
Eur J Clin Invest; 2002 Dec; 32(12):882-8. PubMed ID: 12534446
[TBL] [Abstract][Full Text] [Related]
15. Antioxidant effect of Iloprost: current knowledge and therapeutic implications for systemic sclerosis.
Erre GL; Passiu G
Reumatismo; 2009; 61(2):90-7. PubMed ID: 19633795
[TBL] [Abstract][Full Text] [Related]
16. Effects of long-term cyclic iloprost therapy in systemic sclerosis with Raynaud's phenomenon. A randomized, controlled study.
Scorza R; Caronni M; Mascagni B; Berruti V; Bazzi S; Micallef E; Arpaia G; Sardina M; Origgi L; Vanoli M
Clin Exp Rheumatol; 2001; 19(5):503-8. PubMed ID: 11579708
[TBL] [Abstract][Full Text] [Related]
17. Cytokine mRNA profile of alveolar T lymphocytes and macrophages in patients with systemic sclerosis suggests a local Tr1 response.
Andersen GN; Nilsson K; Nagaeva O; Rantapää-Dahlqvist S; Sandström T; Mincheva-Nilsson L
Scand J Immunol; 2011 Sep; 74(3):272-281. PubMed ID: 21535076
[TBL] [Abstract][Full Text] [Related]
18. Effects of Longterm Treatment with Bosentan and Iloprost on Nailfold Absolute Capillary Number, Fingertip Blood Perfusion, and Clinical Status in Systemic Sclerosis.
Trombetta AC; Pizzorni C; Ruaro B; Paolino S; Sulli A; Smith V; Cutolo M
J Rheumatol; 2016 Nov; 43(11):2033-2041. PubMed ID: 27744392
[TBL] [Abstract][Full Text] [Related]
19. Cyclosporin A and iloprost treatment of systemic sclerosis: clinical results and interleukin-6 serum changes after 12 months of therapy.
Filaci G; Cutolo M; Scudeletti M; Castagneto C; Derchi L; Gianrossi R; Ropolo F; Zentilin P; Sulli A; Murdaca G; Ghio M; Indiveri F; Puppo F
Rheumatology (Oxford); 1999 Oct; 38(10):992-6. PubMed ID: 10534551
[TBL] [Abstract][Full Text] [Related]
20. Iloprost treatment reduces TNF-alpha production and TNF-RII expression in critical limb ischemia patients without affecting IL6.
Di Renzo M; Pieragalli D; Meini S; De Franco V; Pompella G; Auteri A; Pasqui AL
Prostaglandins Leukot Essent Fatty Acids; 2005 Nov; 73(5):405-10. PubMed ID: 16095891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
